Lexapro (Escitalopram): Uses, Dosage, Side Effects, and Precautions
Lexapro (generic: escitalopram) is a selective serotonin reuptake inhibitor (SSRI) approved by the FDA for major depressive disorder (MDD) and generalized anxiety disorder (GAD) in adults and adolescents (12+). It is the S-enantiomer of citalopram, offering greater potency and selectivity for the serotonin transporter.
FDA-Approved Indications
- Major Depressive Disorder (MDD): Adults and adolescents ≥12 years
- Generalized Anxiety Disorder (GAD): Adults
Common Off-Label Uses
- Social anxiety disorder (SAD)
- Panic disorder
- Obsessive-compulsive disorder (OCD)
- Post-traumatic stress disorder (PTSD)
- Premenstrual dysphoric disorder (PMDD)
- Vasomotor symptoms of menopause
Dosage Guidelines
| Condition | Starting Dose | Target/Max Dose |
| MDD (adults) | 10 mg daily | 10–20 mg daily |
| GAD (adults) | 10 mg daily | 10–20 mg daily |
| Adolescents (MDD) | 10 mg daily | 10–20 mg daily |
| Elderly/hepatic impairment | 10 mg daily | 10 mg daily (max) |
Dose adjustments: Increase after ≥1 week if needed. Maximum 20 mg/day. Taper gradually on discontinuation.
Common Side Effects (≥5% incidence)
- Nausea, diarrhea, dry mouth
- Insomnia or somnolence
- Fatigue, dizziness
- Hyperhidrosis (excessive sweating)
- Sexual dysfunction (delayed orgasm, decreased libido, erectile dysfunction)
- Weight changes (gain more common long-term)
Serious Risks & Warnings
- Boxed warning: Increased suicidal ideation/behavior in patients <25 years during initial treatment
- Serotonin syndrome: With MAOIs, other serotonergic drugs, linezolid, methylene blue
- QT prolongation: Caution with other QT-prolonging drugs, electrolyte abnormalities
- Hyponatremia (SIADH): Especially elderly, diuretic users
- Bleeding risk: With NSAIDs, anticoagulants, antiplatelets
- Activation of mania: Screen for bipolar disorder
- Discontinuation syndrome: Dizziness, sensory disturbances, anxiety, irritability—taper over ≥2 weeks
Contraindications & Precautions
- Concurrent MAOI use (or within 14 days)
- Pimozide (QT risk)
- Pregnancy (Category C): Weigh risks/benefits; third-trimester exposure risks neonatal adaptation syndrome
- Breastfeeding: Excreted in milk; monitor infant
- Renal/hepatic impairment: Dose adjustment
Monitoring
Assess suicide risk at initiation and dose changes. Monitor weight, sodium, and bleeding signs periodically. Evaluate response at 4–6 weeks; continue 6–12 months after remission to prevent relapse.
Prescription Medications - Related Articles